It's really interesting, because right now, as we have significant capacity and access to vaccines, the real challenge is really the deployment of these vaccines in different countries.
If we take the example of our mRNA technology, there is a challenge related to the cold chain process. We need to make sure that the delivery of the vaccine respects the very strict guidance that applies to the cold chain. We've realized that some countries might not have the capabilities right now, or did not have them in the past, to actually be able to fully deliver our vaccines as quickly as they would like to. This is a limitation that we need to be aware of.
Our role is to help these countries get the equipment required—for instance, ultra-low temperature freezers to make sure they can store the vaccines safely—and also help them to optimally deploy the vaccines to their population. We always know that the last mile is very important. We need to make sure that we can provide the vaccines to where the people are. That process is quite complex. We probably need to have more investments in infrastructure in these countries.